606 related articles for article (PubMed ID: 33001024)
1. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.
Walton M; Wade R; Claxton L; Sharif-Hurst S; Harden M; Patel J; Rowe I; Hodgson R; Eastwood A
Health Technol Assess; 2020 Sep; 24(48):1-264. PubMed ID: 33001024
[TBL] [Abstract][Full Text] [Related]
2. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
4. Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.
Wade R; South E; Anwer S; Sharif-Hurst S; Harden M; Fulbright H; Hodgson R; Dias S; Simmonds M; Rowe I; Thornton P; Eastwood A
Health Technol Assess; 2023 Dec; 27(29):1-172. PubMed ID: 38149643
[TBL] [Abstract][Full Text] [Related]
5. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
6. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.
Fleeman N; Houten R; Bagust A; Richardson M; Beale S; Boland A; Dundar Y; Greenhalgh J; Hounsome J; Duarte R; Shenoy A
Health Technol Assess; 2020 Jan; 24(2):1-180. PubMed ID: 31931920
[TBL] [Abstract][Full Text] [Related]
8. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK.
Pollock RF; Colaone F; Guardiola L; Shergill S; Brennan VK
J Med Econ; 2020 Jun; 23(6):593-602. PubMed ID: 32067534
[No Abstract] [Full Text] [Related]
11. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman OM; Elsayed Z
Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
[TBL] [Abstract][Full Text] [Related]
12. VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials.
Gebski V; Gibbs E; Gandhi M; Chatellier G; Dinut A; Pereira H; Chow PK; Vilgrain V
JMIR Res Protoc; 2017 Feb; 6(2):e17. PubMed ID: 28202430
[TBL] [Abstract][Full Text] [Related]
13. External beam radiotherapy for unresectable hepatocellular carcinoma.
Abdel-Rahman O; Elsayed Z
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011314. PubMed ID: 28267205
[TBL] [Abstract][Full Text] [Related]
14. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
15. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
[TBL] [Abstract][Full Text] [Related]
16. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman O; Elsayed Z
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011313. PubMed ID: 31978267
[TBL] [Abstract][Full Text] [Related]
17. Methods for selecting the best evidence to inform a NICE technology appraisal on selective internal radiation therapies for hepatocellular carcinoma.
Wade R; Sharif-Hurst S; Harden M; Walton M; Claxton L; Hodgson R; Eastwood A
Syst Rev; 2020 Aug; 9(1):184. PubMed ID: 32799923
[TBL] [Abstract][Full Text] [Related]
18. Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.
Roccarina D; Majumdar A; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011649. PubMed ID: 28281295
[TBL] [Abstract][Full Text] [Related]
19. The Cost-Effectiveness of Selective Internal Radiation Therapies Compared With Sorafenib for Treating Advanced Unresectable Hepatocellular Carcinoma in the United Kingdom.
Claxton L; Walton M; Sharif-Hurst S; Wade R; Eastwood A; Hodgson R
Value Health; 2022 May; 25(5):787-795. PubMed ID: 35500948
[TBL] [Abstract][Full Text] [Related]
20. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.
Garin E; Tselikas L; Guiu B; Chalaye J; Edeline J; de Baere T; Assenat E; Tacher V; Robert C; Terroir-Cassou-Mounat M; Mariano-Goulart D; Amaddeo G; Palard X; Hollebecque A; Kafrouni M; Regnault H; Boudjema K; Grimaldi S; Fourcade M; Kobeiter H; Vibert E; Le Sourd S; Piron L; Sommacale D; Laffont S; Campillo-Gimenez B; Rolland Y;
Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):17-29. PubMed ID: 33166497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
